Drugs in R & D

, Volume 4, Issue 1, pp 55–56 | Cite as

Morphine/Dextromethorphan — Endo

E 3231, Morphidex
Adis R&D Profile


Morphine Chronic Pain NMDA Receptor Cancer Pain Oxycodone 


  1. 1.
    Caruso FS, Minn FL, Mao J, et al. NMDA antagonists enhance the analgesic properties of opiates. International Journal of Tissue Reactions 19: 28, No. 1/2, 1997Google Scholar
  2. 2.
    Algos Pharmaceutical Corporation. Algos Pharmaceutical Corporation releases results of phase III clinical trials for its lead product MorphiDex-tm. Media Release: [2 pages], 15 Sep 1998Google Scholar
  3. 3.
    Algos Pharmaceutical Corporation. Algos Pharmaceutical Corporation announces additional phase III clinical trial data for its lead product MorphiDex. Media Release: [2 pages], 25 Sep 1998Google Scholar
  4. 4.
    Endo Pharmaceuticals Holdings Inc. Endo Pharmaceuticals Announces Results from MorphiDex(R) Phase III Clinical Trial. Media Release: 24 Jun 2002. Available from URL: http://www.endo.com Google Scholar

Copyright information

© Adis International Limited 2003

Personalised recommendations